Matt Giacalone

Company: Vaxiion Therapeutics

Job title: Chief Executive Officer

Seminars:

VAX014 Co-Delivers STING/RIG-I Agonists with a Novel Oncolytic Mechanism to Facilitate Robust in situ Immunization Prior to Systemic Checkpoint Blockade 4:30 pm

• How VAX014, a novel tumor-targeted oncolytic agent based on recombinant bacterial minicells can facilitate in situ immunization • Nonclinical data to support VAX014's ability to function optimally in STING/RIG-I positive tumors • Nonclinical data to show that VAX014 in combination with immune checkpoint inhibitors gives additive benefit in the treatment of solid tumorsRead more

day: Day One